J&J's Mammen out of running for top Biogen job; pharma helped finance committees that support election deniers

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Amid concerns over U.S. democracy, pharma helped finance committees that support election deniers By Ed Silverman Adobe Major pharmaceutical companies have contributed to organizations that funneled money toward Republicans who denied the 2020 election results. Read More STAT+: After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results By Ed Silverman Adobe The moves comes after the NIH was criticized for failing to ensure results of roughly half of clinical trials the agency funded were reported. Read More STAT+: J&J's Mammen out of the running for Biogen CEO post By Adam Feuerstein and Matthew Herper and Damian Garde Venrock One person familiar with the matter said one sticking point was that Mamman wanted influence over the future makeup of Biogen’s board. Read More Sponsored Insight by STAT TRIALS PULSE Find patterns in clinical trials data for clear decision-making that will get you ahead. STAT Trials Pulse combines machine learning and STAT's award-winning newsroom to help you reduce information overload and identify the signals that matter in the clinical trials landscape. Build watch lists to monitor the companies and therapeutic areas you care about, receive personalized email briefings about your followed trials, and decode patterns you wouldn't otherwise see. Learn more at statnews.com/trials-pulse, or start your 30-day free trial. STAT+: FDA places clinical hold on Verve Therapeutics gene-editing treatment By Adam Feuerstein Adobe The therapy, VERVE-101, uses a form of CRISPR to treat familial hypercholesterolemia, a a relatively common form of high cholesterol. Read More Monday, November 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser